Andy Holt
CCO, Viralgen | AAV Gene-Therapy Manufacturing
Andy Holt is the chief commercial officer of Viralgen, a contract development and manufacturing organization (CDMO) specializing in the production of adeno-associated virus (AAV) gene therapies. He has spent roughly eighteen years in cell and gene therapy testing, development, and manufacturing, working largely on the CDMO side to expand access to and lower the cost of advanced medicines.
Holt began his career as a molecular biologist before moving into the commercial side of the industry. He held business development and management roles at MilliporeSigma (part of Merck KGaA) and Lonza, and served as vice president of business development at AskBio before that company’s acquisition by Bayer. Most recently, before returning to Viralgen, he was chief commercial officer of the affiliated companies Ncardia and Cellistic, which apply induced pluripotent stem cell (iPSC) technology to drug discovery and allogeneic cell therapy. He rejoined Viralgen, an independently operated subsidiary of AskBio (itself owned by Bayer), as its chief commercial officer in 2023, having previously served there as executive vice president of commercial development and manufacturing.
Holt appeared on Open Door Salon alongside Phil Vanek, chief commercialization officer of the International Society for Cell and Gene Therapy (ISCT), for a conversation on why cell and gene therapies remain so expensive and what it would take to make them broadly affordable. Holt’s central argument was that manufacturing cost is no longer the primary barrier to access: the same fundamental tools, he noted, are already being used to commercialize CAR-T therapy in other health systems at a fraction of the U.S. price.
Across the conversation he and Vanek examined the structural reasons advanced therapies stay costly: the education gap among clinicians and patients, payer incentives shaped by employment-linked insurance, the rising bar for clinical evidence, and the pull of capital toward artificial intelligence and away from advanced therapeutics. Holt also offered practical guidance for founders, arguing that the path to translation runs through operational discipline rather than novelty.
Frequently Asked Questions About Andy Holt
What is Andy Holt an expert in?
Andy Holt is an expert in cell and gene therapy manufacturing and commercialization, with particular depth in adeno-associated virus (AAV) gene therapies and contract development and manufacturing (CDMO) operations. His focus is expanding access to and lowering the cost of advanced medicines.
Who is Andy Holt?
Andy Holt is the chief commercial officer of Viralgen, a CDMO specializing in AAV gene therapies. He has spent roughly eighteen years in cell and gene therapy, beginning as a molecular biologist before moving to the commercial side, with prior roles at MilliporeSigma, Lonza, AskBio, and the iPSC companies Ncardia and Cellistic. He appeared on Open Door Salon, the life sciences podcast hosted by Lori Ellis.
How does Andy Holt think about the cost of cell and gene therapies?
Andy Holt argues that manufacturing cost is no longer the primary barrier to access, noting that the same fundamental tools are already used to commercialize CAR-T therapy in other health systems at a fraction of the US price. He points to structural barriers instead, the education gap among clinicians and patients, payer incentives shaped by employment-linked insurance, the rising bar for clinical evidence, and capital flowing toward AI, and advises founders that translation runs through operational discipline rather than novelty.
What organizations is Andy Holt affiliated with?
Andy Holt is chief commercial officer of Viralgen, an independently operated subsidiary of AskBio, which is owned by Bayer. Earlier in his career he held roles at MilliporeSigma (part of Merck KGaA), Lonza, AskBio, and the affiliated companies Ncardia and Cellistic.
On Open Door Salon
“The $50,000 Cure Problem: Why the US Can't Do What India Already Did”
Andy Holt & Phil Vanek · February 10, 2026
Episode page & show notes on Open Door Salon
In this episode
- Cell & gene therapy: promise vs. reality of clinical adoption
- Why manufacturing cost is no longer the biggest barrier
- CAR-T commercialized in India for under $50,000 — same tools, different system
- The education problem: clinicians and patients learning at the same time
- Why payers think like investors — and what that means for adoption
- The $4 million problem: employment-linked healthcare creates reverse incentives
- First-in-human in under a year for under $20 million — it's possible
- NIH funding uncertainty: spend every dollar like it's your last
- AI as the "shiny object" siphoning capital from advanced therapies
- Advice for startups: hunt for boring — keep your therapy as the only variable
- "Science is magic that works"
Topics
Watch on Open Door Salon
Open Door Salon brings life-sciences leaders into candid conversation. Every Monday, the week's takeaways land in your inbox.
Subscribe on Substack →